Exact Sciences stock holds steady as investors look to upcoming results
Published on 08/28/2026 at 08:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exact Sciences (US30063P1057) stock is trading steadily in late August 2026 as investors weigh the company’s recent growth in cancer diagnostics and screening against expectations for its next earnings update.
Growth story in cancer screening
Exact Sciences focuses on advanced cancer diagnostics and colorectal cancer screening tests, a market where demand has expanded over recent years as health systems push for earlier detection and broader screening coverage.
In its most recent reported quarter within the past year, the company has highlighted rising revenue from its flagship colorectal cancer screening product, with test volumes and reimbursement coverage supporting double digit growth compared with the prior year period.
Earnings outlook and analyst expectations
Analysts following Exact Sciences are focused on how the next earnings report will balance continued investment in research and development with the company’s path toward sustained profitability.
Consensus expectations for the current year reflect revenue growth in the mid-teens percentage range and improving adjusted earnings per share versus the prior year, as the company benefits from greater operating leverage over its cost base.
Key product in colorectal cancer screening
One of Exact Sciences’ key commercial products is its noninvasive stool-based colorectal cancer screening test, which allows eligible adults to complete screening at home and send samples to the company’s laboratories for analysis.
This test has become a widely used option for colorectal cancer screening alongside colonoscopy, supported by guideline recommendations and coverage by major payers, and remains central to the company’s growth strategy.
Shares and recent trading context
Exact Sciences shares are listed in the United States and trade in US dollars, giving US retail investors direct exposure to the company’s cancer diagnostics growth story.
As of late August 2026, the stock is trading below its 52-week high but above its 52-week low, leaving room for potential movement when the next set of quarterly figures and updated guidance are released.
Fact box
Company: Exact Sciences Corp.
ISIN: US30063P1057
Ticker: EXAS
Exchange: Nasdaq
Sector / Industry: Health care / Diagnostics
